SCHEMBL20711869

SCHEMBL20711869

CCN1CC(N(C)C(C)C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12885059 0.84 GBA1 (0.36)
SCHEMBL14388283 0.84 SMN1; SMN2 (0.32)
SCHEMBL24192655 0.81 CYP3A4 (0.33)
SCHEMBL26726833 0.80 NOS3 (0.33)
SCHEMBL24941815 0.80 PIK3CD (0.45)
SCHEMBL13860753 0.78 SMN1; SMN2 (0.38)
SCHEMBL10198502 0.75
SCHEMBL20063340 0.75 JAK2 (0.33)
SCHEMBL22388075 0.74 PIK3CD (0.47)
SCHEMBL14883743 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392368-B2 Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-08-27 US disclosed
US-20190040043-A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-02-07 US disclosed